NovaBridge Biosciences
BioSniper Score
2-factor signal · derived from public data
N/A
D/E 0.13 · 0% dilution
N/A
N/A
N/A
1 buy · 2 sells (180d)
A transparent, data-derived signal for NovaBridge Biosciencesacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$185.0M
Cash
$210.6M
Quarterly Burn
—
Runway
—
Revenue
—
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
45
Total value held
$71.4M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 12,065,300 | $29.6M |
| hhlr advisors, ltd. | 5,980,568 | $14.7M |
| morgan stanley | 3,838,198 | $9.4M |
| aihc capital management ltd | 2,262,933 | $5.6M |
| adage capital partners gp, l.l.c. | 1,000,000 | $2.5M |
| blackrock, inc. | 627,496 | $1.5M |
| exome asset management llc | 576,960 | $1.4M |
| state street corp | 370,107 | $910K |
| fiera capital corp | 315,681 | $777K |
| barclays plc | 299,299 | $736K |
Showing top 10 of 45 institutional holders of NovaBridge Biosciences. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
What is NovaBridge Biosciences's market capitalization?
NovaBridge Biosciences's market capitalization is approximately $185.0M.
Who is the CEO of NovaBridge Biosciences?
Dr. Xi-Yong Fu M.B.A., Ph.D. is the chief executive officer of NovaBridge Biosciences (NBP).
Get the full picture on NovaBridge Biosciences
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.